Cargando…

Serum Levels of the Cancer-Testis Antigen POTEE and Its Clinical Significance in Non-Small-Cell Lung Cancer

BACKGROUND: POTEE (POTE ankyrin domain family, member E) is a newly identified cancer-testis antigen that has been found to be expressed in a wide variety of human cancers including cancers of the colon, prostate, lung, breast, ovary, and pancreas. AIM: To measure the serum levels of POTEE in patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qi, Li, Xuefei, Ren, Shengxiang, Cheng, Ningning, Zhao, Mingchuan, Zhang, Yishi, Li, Jiayu, Cai, Weijing, Zhao, Chao, Cao, Wa, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393100/ https://www.ncbi.nlm.nih.gov/pubmed/25860145 http://dx.doi.org/10.1371/journal.pone.0122792

Ejemplares similares

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients
por: Li, Xuefei, et al.
Publicado: (2014)

Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer
por: Cheng, Ningning, et al.
Publicado: (2015)

MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type
por: Li, Jiayu, et al.
Publicado: (2014)

Expression of the POTE gene family in human ovarian cancer
por: Barger, Carter J, et al.
Publicado: (2018)

Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples()()
por: Zhao, Chao, et al.
Publicado: (2014)

Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer
por: Pan, Hui, et al.
Publicado: (2016)

In silico approach to understand epigenetics of POTEE in ovarian cancer
por: Qazi, Sahar, et al.
Publicado: (2021)

BESFA: bioinformatics based evolutionary, structural & functional analysis of prostrate, Placenta, Ovary, Testis, and Embryo (POTE) paralogs
por: Qazi, Sahar, et al.
Publicado: (2022)

Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma
por: Wang, Qi, et al.
Publicado: (2016)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE
por: Huang, Yi-Hsiang, et al.
Publicado: (2013)

POTEE drives colorectal cancer development via regulating SPHK1/p65 signaling
por: Shen, Zhiyong, et al.
Publicado: (2019)

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
por: Zhao, Chao, et al.
Publicado: (2020)

Evolutionary Dynamics of the POTE Gene Family in Human and Nonhuman Primates
por: Maggiolini, Flavia Angela Maria, et al.
Publicado: (2020)

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
por: Jia, Yijun, et al.
Publicado: (2020)

Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
por: Zhou, Juan, et al.
Publicado: (2019)

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
por: Wang, Yan, et al.
Publicado: (2018)

Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma
por: Zhou, Jin-xue, et al.
Publicado: (2011)

Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers
por: Jiang, Tao, et al.
Publicado: (2018)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
por: Li, Xuefei, et al.
Publicado: (2016)

Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer
por: Chen, Xiaoxia, et al.
Publicado: (2020)

Cancer testis antigen and immunotherapy
por: Krishnadas, Deepa Kolaseri, et al.
Publicado: (2013)

Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer()
por: Jiang, Tao, et al.
Publicado: (2017)

Multi-cancer blood testing combined with PET-CT: road for hope to screen for cancer and guide intervention
por: Jiang, Tao, et al.
Publicado: (2020)

Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis
por: Lin, Lina, et al.
Publicado: (2021)

Association between Single Nucleotide Polymorphisms (SNPs) and Toxicity of Advanced Non-Small-Cell Lung Cancer Patients Treated with Chemotherapy
por: Zhang, Ling, et al.
Publicado: (2012)

N-Myristoylation by NMT1 Is POTEE-Dependent to Stimulate Liver Tumorigenesis via Differentially Regulating Ubiquitination of Targets
por: Zhu, Guoqing, et al.
Publicado: (2021)

Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors
por: Liu, Sangtian, et al.
Publicado: (2020)

Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
por: Jiang, Tao, et al.
Publicado: (2017)

Expression of cancer–testis antigens in esophageal cancer and their progress in immunotherapy
por: Zhang, Yujie, et al.
Publicado: (2019)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
por: He, Yayi, et al.
Publicado: (2016)

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021)

Qua pote quisque, in ea conterat arte diem: COVID-19 and Australian and New Zealand intensive care
por: Udy, Andrew
Publicado: (2023)

Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma
por: Li, Xisheng, et al.
Publicado: (2017)

Cancer testis antigen subfamilies: Attractive targets for therapeutic vaccine (Review)
por: Ren, Shengnan, et al.
Publicado: (2023)

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2(nd)/3(rd) Line Therapy in Patients with Lung Adenocarcinoma
por: He, Yayi, et al.
Publicado: (2016)

Cancer/testis antigens (CTAs) expression in resected lung cancer
por: Jin, Shi, et al.
Publicado: (2018)

The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection
por: Shi, Jinpeng, et al.
Publicado: (2021)

Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer
por: Nin, Dawn Sijin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kv34i1ru6fkvbarea6leqh7vnb